The Lover app is the first sex therapy app to receive US Food and Drugs Administration (FDA) approval


Lovers Leadership Team

“We’re thrilled to be the first FDA-cleared digital therapy for sex,” said co-founder Nick Pendle. “Since our launch, Lover has always strived to be the most effective sexual wellness app, and has proven to be so with 86% of users reporting improvement within 2 weeks.”

Lover, the digital therapy app to improve users’ sex lives and treat sexual problems, today announced that the app has been approved by the FDA and joined the FDA’s Safer Technologies STeP program. With this recognition, Lover users can make fundamental changes to their sex lives. The FDA said Lover has been shown to provide “a significant safety benefit in the treatment or diagnosis of less serious diseases or conditions” and “may also provide a significant public health benefit.”

Through the STep program, which aims to give people access to safer medical devices to improve health outcomes, Lover prides itself on being a science-based approach to solving sexual problems and guides its users through a process of self-discovery with personalized advice and training. contents. After a private 30-minute consultation of personalized 1-2-1 coaching and goal setting, clinically proven tips and exercises are conducted to guide users towards a fulfilling and healthy sex life, essential for personal well-being and to relationship satisfaction.

This news follows Lover’s closing of its latest funding round, a bridge totaling $2 million led by investors including Lerer Hippeau, Manta Ray, Global Founders Capital and FJ Labs. These significant investments and evidence will support Lover’s continued growth in 2022, providing customers with an unprecedented mobile sexual healthcare experience.

“We’re thrilled to be the first FDA-cleared digital therapy for sex,” said co-founder Nick Pendle. “Since our launch, Lover has always aimed to be the most effective sexual wellness app on the market, and has proven to be such with 86% of users reporting improvement within 2 weeks of using the courses. Lover’s FDA approval of their STeP program is the ultimate endorsement of this.

“At Lover, we believe that the product, exercises and educational content we have created with our medical expert, Dr. Britney Blair, and her team of experts can help millions of people enjoy a better sex life. and happier relationships,” says co-founder Jas Bagniewski. “We have been proven to be a safe and effective way to treat sexual issues. Lover works, and we couldn’t be prouder that after rigorous review, the FDA agreed with us.”

Lover is free to download, and the first activity in your custom goal is free. There are three subscription options: 3 month access for $59.99, annual access for $119.99, or lifetime access for $249.99.

The terms and privacy policy can be read here: To download the Lover app, go to or go to the App Store.

About the lover

Lover is an FDA-cleared digital therapy tool that personalizes a journey to sexual wellness and helps people have the sex life they want and deserve. The app uses science-based exercises, tools, and expert advice developed by sex therapists and clinical psychologists to help people better understand their bodies, communicate better in their sexual relationships, and have a more pleasurable and enjoyable sex life. fulfilling. The Lover app was developed by Dr. Britney Blair, clinical psychologist and sexologist, and her team of sexual wellness experts. For more information, visit

About the United States Food and Drug Administration (FDA)

The Food and Drug Administration (FDA) is the federal agency responsible for protecting public health by regulating food safety, drugs, manufacturing, medical devices, and many other industries. Anyone with sufficient coding knowledge can publish an app. The FDA therefore began to offer an approval process for these applications to demonstrate their effectiveness.

About STEP

The Safer Technologies Program (STeP) is a voluntary program for specific medical devices and device-based combination products that are reasonably expected to significantly improve the safety of currently available treatments or diagnostics that target an underdeveloped disease or condition. underlying. STeP-eligible devices may include devices intended to treat or diagnose diseases or conditions that are not life-threatening or reasonably reversible.

Share the article on social networks or by e-mail:


Comments are closed.